Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study

The Lancet Infectious Diseases

Volumn 17, Issue 8, 2017, Pages 854-866

  Heppner, D G ^f   Kemp, T L ^f   Martin, B K ^f   Ramsey, W J ^f   Nichols, R ^f   Dasen, E J ^f   Link, C ^f   Das, R ^f   Xu, Z J ^f   Sheldon, E A ^f   Nowak, T ^f   Monath, T P ^f   Fusco, J ^f   Crowell, J ^f   Creager, J ^f   Klein, R ^f   Gerstenberger, E ^f   Bliss, R ^f   Feldman, R A ^f   Essink, Brandon J ^f   Smith, W B ^f   Chu, L ^f   Seger, W M ^f   Saleh, J ^f   Borders, J L ^f   Adams, M ^f   more..

^a NEWLINK GENETICS   (United States)

^b Merck & Co ^*  (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d MIAMI RESEARCH ASSOCIATES   (United States)

^e Veristat   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; PLACEBO; RECOMBINANT PROTEIN; RECOMBINANT VESICULAR STOMATITIS VIRUS ZAIRE EBOLA VIRUS ENVELOPE GLYCOPROTEIN; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS RNA; DRUG CARRIER; RECOMBINANT VACCINE; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ABDOMINAL PAIN; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARM PAIN; ARTHRALGIA; ARTHRITIS; ARTICLE; CHILL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; EBOLA HEMORRHAGIC FEVER; ENZYME LINKED IMMUNOSORBENT ASSAY; ET VARIOLIFORMIS ACUTA; FATIGUE; FEMALE; FEVER; HEADACHE; HEMOPHAGOCYTIC SYNDROME; HUMAN; INJECTION SITE FIRMNESS; INJECTION SITE REACTION; JOINT STIFFNESS; JOINT SWELLING; KNEE OSTEOARTHRITIS; LOW DRUG DOSE; LOWER LIMB; MACULAR RASH; MALE; MIDDLE AGED; MOUTH ULCER; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; MUSCULOSKELETAL STIFFNESS; MYALGIA; NAUSEA; NORMAL HUMAN; OBJECTIVE FEVER; ORAL MUCOSAL DISEASE; PAPULAR RASH; PERIVASCULAR LYMPHOHISTIOCYTIC INFLAMMATION; PETECHIA; PHASE 1 CLINICAL TRIAL; PHLEBOTOMY; PITYRIASIS LICHENOIDES; POLYARTHRITIS; PRIORITY JOURNAL; PROXIMAL INTERPHALANGEAL JOINT; PURPURA; PURPURIC RASH; RANDOMIZED CONTROLLED TRIAL; RANGE OF MOTION; RASH; SEROCONVERSION; SHIVERING; SIDE EFFECT; SKIN DEFECT; SKIN MASS; SKIN REDNESS; SKIN ULCER; SUBJECTIVE FEVER; SWEAT GLAND DISEASE; SYNOVITIS; TEMPOROMANDIBULAR JOINT DISORDER; TENDINITIS; TREATMENT DURATION; TREATMENT OUTCOME; VACCINATION; VACCINE IMMUNOGENICITY; VESICULAR RASH; VIRUS NEUTRALIZATION; VOMITING; ADOLESCENT; BLOOD; CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EBOLAVIRUS; GENE VECTOR; GENETICS; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; INCIDENCE; INTRAMUSCULAR DRUG ADMINISTRATION; PATHOLOGY; SERODIAGNOSIS; UNITED STATES; VESICULOVIRUS; VIRAL PLAQUE ASSAY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; DRUG CARRIERS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EBOLA VACCINES; EBOLAVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VECTORS; HEALTHY VOLUNTEERS; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNOGLOBULIN G; INCIDENCE; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; PLACEBOS; UNITED STATES; VACCINES, SYNTHETIC; VESICULOVIRUS; VIRAL ENVELOPE PROTEINS; VIRAL PLAQUE ASSAY; YOUNG ADULT;

EID: 85020465407     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(17)30313-4     Document Type: Article

References (30)

1. WHO. Situation report—Ebola virus disease, June 10, 2016 http://apps.who.int/iris/bitstream/10665/208883/1/ebolasitrep_10Jun2016_eng.pdf?ua=1 (accessed April 28, 2017).
2. World Bank Group. 2014–2015 West Africa Ebola crisis: impact update, May 10, 2016 http://pubdocs.worldbank.org/en/297531463677588074/Ebola-Economic-Impact-and-Lessons-Paper-short-version.pdf (accessed April 28, 2017).
3. Mullan, Z, The cost of Ebola. Lancet Glob Health, 3, 2015, e423.
4. Henao-Restrepo, AM, Preziosi, MP, Wood, D, Moorthy, V, Kieny, MP, On a path to accelerate access to Ebola vaccines: the WHO's research and development efforts during the 2014–2016 Ebola epidemic in West Africa. Curr Opin Virol 17 (2016), 138–144.
5. Mire, CE, Miller, AD, Carville, A, et al. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis, 6, 2012, e1567.
6. Marzi, A, Ebihara, H, Callison, J, et al. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J Infect Dis 204 (2011), S1066–S1074.
7. Marzi, A, Feldmann, H, Ebola virus vaccines: an overview of current approaches. Expert Rev Vaccines 13 (2014), 521–531.
8. Garbutt, M, Liebscher, R, Wahl-Jensen, V, et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 78 (2004), 5458–5465.
9. Qiu, X, Fernando, L, Alimonti, JB, et al. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One, 4, 2009, e5547.
10. Jones, SM, Feldmann, H, Ströher, U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 11 (2005), 786–790.
11. Geisbert, TW, Feldmann, H, Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis 204 (2011), S1075–S1081.
12. Marzi, A, Robertson, SJ, Haddock, E, et al. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science 349 (2015), 739–742.
13. Geisbert, TW, Daddario-Dicaprio, KM, Lewis, MG, et al. Vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog, 4, 2008, e1000225.
14. Regules, JA, Beigel, JH, Paolino, KM, et al. A recombinant vesicular stomatitis virus Ebola vaccine. N Engl J Med 376 (2017), 330–341.
15. Agnandji, ST, Huttner, A, Zinser, ME, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe—preliminary report. N Engl J Med 374 (2016), 1647–1660.
16. Huttner, A, Dayer, J-A, Yerly, S, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis 15 (2015), 1156–1166.
17. Rom, DM, Costello, RJ, Connell, LT, On closed test procedures for dose-response analysis. Stat Med 13 (1994), 1583–1596.
18. Gailhardou, S, Skipetrova, A, Dayan, GH, et al. Safety overview of a recombinant live-attenuated tetravalent dengue vaccine: pooled analysis of data from 18 clinical trials. PLoS Negl Trop Dis, 10, 2016, e0004821.
19. Dayan, GH, Pugachev, K, Bevilacqua, J, Lang, J, Monath, TP, Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus. Viruses 5 (2013), 3048–3070.
20. Martins, RM, Maia, ML, Farias, RHG, et al. 17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study. Hum Vaccin Immunother 9 (2013), 879–888.
21. Dayer, JA, Siegrist, CA, Huttner, A, Volunteer feedback and perceptions after participation in a phase I, first-in-human Ebola vaccine trial: an anonymous survey. PLoS One, 12, 2017, e0173148.
22. Halperin, SA, Arribas, JR, Rupp, R, et al. Six-month safety data of recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine in a phase 3 double-blind, placebo-controlled randomized study in healthy adults. J Infect Dis, 2017, 10.1093/infdis/jix189 published online May 26.
23. Ebola ça Suffit Ring Vaccination Trial Consortium. The ring vaccination trial: a novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola. BMJ, 351, 2015, h3740.
24. Henao-Restrepo, AM, Longini, IM, Egger, M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386 (2015), 857–866.
25. Henao-Restrepo, AM, Camacho, A, Longini, IM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet 389 (2017), 505–518.
26. Wilkinson, DR, Page, M, Mattiuzzo, GM, et al. Comparison of platform technologies for assaying antibody to Ebola. Vaccine 35 (2017), 1347–1352.
27. Marzi, A, Engelmann, F, Feldmann, F, et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci USA 110 (2013), 1893–1898.
28. Marzi, A, Hanley, PW, Haddock, E, Martellaro, C, Kobinger, G, Feldmann, H, Efficacy of vesicular stomatitis virus-Ebola virus postexposure treatment in rhesus macaques infected with Ebola virus Makona. J Infect Dis 214 (2016), S360–S366.
29. Dahlke, C, Kasonta, R, Lunemann, S, et al. Dose-dependent T-cell dynamics and cytokine cascade following rVSV-ZEBOV immunization. EBioMedicine 19 (2017), 107–118.
30. Huttner, A, Combescure, C, Grillet, S, et al. A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa. Sci Transl Med, 9, 2017, eaaj1701.